PRODUCT DETAILS
- RLD: TOPROL-XL®
- Strength: Available in 25 mg, 50 mg, 100 mg, and 200 mg extended-release tablets
- Therapeutic Class: Beta-blocker
PRODUCT DETAILS
| Strength | NDC Number | Saleable Unit | Wholesaler Numbers |
|---|---|---|---|
| 25 mg | 70436-202-02 | Bottle of 500 | Cardinal Health: 5807169 |
| McKesson: 2645216 | |||
| Amerisource: 10272523 | |||
| 50 mg | 70436-183-01 | Bottle of 100 | Cardinal Health: 5779434 |
| McKesson: 2608792 | |||
| Amerisource: 10266670 | |||
| 50 mg | 70436-183-02 | Bottle of 500 | Cardinal Health: 5779426 |
| McKesson: 2608800 | |||
| Amerisource: 10266632 | |||
| 100 mg | 70436-166-01 | Bottle of 100 | Cardinal Health: 5719919 |
| McKesson: 2325926 | |||
| Amerisource: 10258004 | |||
| 100 mg | 70436-166-02 | Bottle of 500 | Cardinal Health: 5719927 |
| McKesson: 2325934 | |||
| Amerisource: 10257985 | |||
| 200 mg | 70436-167-01 | Bottle of 100 | Cardinal Health: 5719935 |
| McKesson: 2325991 | |||
| Amerisource: 10258020 | |||
| 200 mg | 70436-167-02 | Bottle of 500 | Cardinal Health: 5719943 |
| McKesson: 2326007 | |||
| Amerisource: 10257956 |
Metoprolol Succinate Extended-Release Tablets USP, 25 mg are white film coated oval shape tablets, scored on two sides, debossed with “Y” and “H” on one side and debossed with “164” on the other side.
Metoprolol Succinate Extended-Release Tablets, USP: 50 mg tablets are white film coated oval shape tablets, scored on two sides, debossed with “Y” and “H” on one side and debossed with “165” on the other side.
Metoprolol Succinate Extended-Release Tablets, USP: 100 mg are white film coated oval shape tablets, scored on one side and debossed with “Y” and “H”, debossed with “163” on the other side.
Metoprolol Succinate Extended-Release Tablets, USP: 200 mg are white film coated oval shape tablets, scored on one side and debossed with “Y” and “H”, debossed with “161” on the other side.
Store at 20° to 25°C (68° to 77°F); excursions permitted to 15° to 30°C (59° to 86°F) [See USP Controlled Room Temperature].
We have been made aware of recent scams that offer false employment opportunities or request financial commitments purportedly on behalf of Slate Run Pharmaceuticals. Unsuspecting job seekers have reported receiving unsolicited contacts such as e-mails and phone calls which may request personal information or offers of employment. Please note that these communications are fraudulent and are not affiliated with Slate Run Pharmaceuticals. Slate Run Pharmaceuticals never requires a financial deposit for employment consideration nor do we offer unsolicited employment packages.
You can reach out to Slate Run Pharmaceuticals at http://www.slaterunpharma.com/get-in-touch/. If you receive a suspicious proposal, please contact your local law enforcement agency for guidance.